FDA Grants Expanded Access to Experimental Pancreatic Cancer Drug for Wider Patient Use
The Food and Drug Administration (FDA) has announced the granting of 'expanded access' to a promising pancreatic cancer drug, allowing it to be administered to a broader group of patients while it is still under regulatory review. This decision comes in response to an application from Revolution Medicines, the manufacturer of the drug, known as daraxonrasib. The FDA's action is aimed at addressing the urgent need for effective treatments for pancreatic cancer, which is one of the most lethal forms of cancer. The expanded access program, also referred to as 'compassionate use,' will be available to patients who have already undergone conventional treatment. Revolution Medicines has committed to providing the drug at no cost to eligible patients, as insurance typically does not cover drugs that have not yet received full approval. 
